Stereotaxis, Inc.
Stereotaxis, Inc.
Your view on STXS
Overview
What the company does, where it operates, and who runs it.
About Stereotaxis, Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- David Leo Fischel C.A.I.A.,
- Headquarters
- 710 North Tucker Boulevard, Saint Louis, MO, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- David Leo Fischel C.A.I.A.,
- Headquarters
- 710 North Tucker Boulevard, Saint Louis, MO, US
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room.
In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters.
Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents.
The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Stereotaxis, Inc. from FRC's valuation model, read against the market price. STXS last traded at $0.84; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Stereotaxis, Inc.. Starting points for Stereotaxis, Inc.: EPS -$0.22, beta 1.40 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Stereotaxis, Inc.. Stereotaxis, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Stereotaxis, Inc.. Trailing twelve-month EPS for Stereotaxis, Inc. stands at -$0.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$3.50
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2015 | Next YearFY Dec 2017 |
|---|---|---|---|---|
| Avg. estimate | -$0.05 | -$0.05 | $2.91 | $2.91 |
| Low estimate | -$0.05 | -$0.05 | $2.72 | $2.72 |
| High estimate | -$0.05 | -$0.05 | $3.03 | $3.03 |
| No. of analysts | 1 | 1 | 14 | 2 |
| Year-ago EPS | -$0.06 | -$0.03 | — | — |
| Growth | +22.2% | -66.7% | — | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2015 | Next YearFY Dec 2017 |
|---|---|---|---|---|
| Avg. estimate | $10.03M | $9.50M | $120.60M | $120.60M |
| Low estimate | $10.03M | $9.50M | $114.48M | $114.48M |
| High estimate | $10.03M | $9.50M | $124.46M | $124.46M |
| No. of analysts | 2 | 2 | 15 | 2 |
| Year-ago revenue | $8.64M | $6.29M | — | — |
| Growth | +16.1% | +51.0% | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from Pulse 2.0; as of Nov 14, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Stereotaxis, Inc.. Stereotaxis, Inc. has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- CLPTClearPoint Neuro, Inc.Medical - Devices$272M
- MBOTMicrobot Medical Inc.Medical - Devices$66M
- NPCENeuroPace, Inc.Medical - Devices$259M
- SSIISS Innovations International, Inc.Medical - Devices$333M
More Medical - Instruments & Supplies companies
- SVSOSheerVision, Inc.OTC$2,551
- TCGGYTecan Group AGOTC$2.3B
- TCHBFTecan Group AGOTC$2.2B
- TDVXFTobii Dynavox AB (publ)OTC$982M
- TFXTeleflex IncorporatedNYSE$6.2B
- TGLVYTop Glove Corporation Bhd.OTC$1.1B
- TRJ.AXTrajan Group Holdings LimitedASX
- TRUMFTerumo CorporationOTC$18.9B
- TRUMYTerumo CorporationOTC$19.5B
- TSNLFTristel PLCOTC$288M
- TUTHStandard Dental Labs Inc.OTC$3M
- UTMDUtah Medical Products, Inc.NASDAQ$205M
ETFs holding Stereotaxis, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- IWMiShares Russell 2000 ETF$76.6B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- IWOiShares Russell 2000 Growth ETF$13.7B in assets0.00%
- VTWOVanguard Russell 2000 ETF$16.6B in assets0.00%
- IWCiShares Micro-Cap ETF$1.3B in assets0.02%
- VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.01%
- SMMDiShares Russell 2500 ETF$4.1B in assets0.00%
Largest holders first, then the funds most concentrated in STXS.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Stereotaxis, Inc., and how their positions are changing. At a $84.5M market value, institutional positions materially move Stereotaxis, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Stereotaxis, Inc. executives and directors. Shares of Stereotaxis, Inc. have traded between $1.54 and $3.59 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Stereotaxis, Inc.. Coverage tracks Stereotaxis, Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Stereotaxis, Inc.